Snapshot · Regeneron Pharmaceuticals, Inc. (REGN)

Data as of 2026-10-18T09:44:20.760Z

Fundamentals check

Market cap

$81.4B

P/E (TTM)

18.9

Gross margin

84.9%

Net margin

27.9%

ROE

13.8%

R&D / revenue

41.6%

Dividend yield

0.5%

FCF yield

4.3%

Latest dividend: $0.94/share (ex-date 2026-08-18, quarterly)

Summary

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

How it makes money

Revenue mix, latest fiscal year

• Collaboration Revenue51.1%
• Product44%
• Product and Service, Other4.9%

Recent Events

• 2026-10-14T00:00:00.000Zpositive

  Price move: REGN rose 3.4%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-01T01:00:00.000Zpositive

  Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

  可能与Regeneron与Sanofi扩大全球联盟、增加前瞻性长效抗体相关，恰逢市场关注点，但不构成严格因果。

  Source: globenewswire.com

• 2026-09-28T00:00:00.000Znegative

  Price move: REGN fell 4.5%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-09-02T00:00:00.000Zpositive

  Price move: REGN rose 3.4%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-19T00:00:00.000Zpositive

  Price move: REGN rose 3.8%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-10T00:00:00.000Zpositive

  Price move: REGN rose 3.0%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-30T00:00:00.000Zpositive

  Price move: REGN rose 6.2%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $849.39 from 18 analysts (last quarter)

Recent rating changes

• 2026-10-15 · UBS Upgraded → Buy

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-10-14SellMURPHY ANDREW J(officer: Co-Chief Scientific Officer)50 shares
• 2026-10-14SellMURPHY ANDREW J(officer: Co-Chief Scientific Officer)463 shares
• 2026-10-14SellMURPHY ANDREW J(officer: Co-Chief Scientific Officer)380 shares
• 2026-10-14SellMURPHY ANDREW J(officer: Co-Chief Scientific Officer)454 shares
• 2026-10-14SellMURPHY ANDREW J(officer: Co-Chief Scientific Officer)38 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。